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INTRODUCTION 
 
In 1960 Ikehara reported the synthesis of a compound he described as 6-
deoxyuridine (5a).1  However, the structure of this compound ⎯prepared by the coupling 
of the chloromercuri salt of 2-(1H)-pyrimidinone (2) with 1-chloro-2,3,5-tri-O-benzoyl-
D-ribofuranoside (1)⎯ was disputed by several workers who synthesized the correct 
compound by the same chloromercuri method,2-4 or by other methods including the 
desulfurization of 4-thiouracil derivatives,5,6 and the silyl variant of the Hilbert-Johnson 
reaction using 3, a procedure more commonly known as the Vorbrüggen reaction 
(Scheme 1).7,8  Compound 5a, which we later named zebularine,9is the structural 
counterpart of the purine natural product nebularine (6).10 Earlier biochemical 
investigations identified zebularine as a bacteriostat,11 and later we and others established 
that it was a potent inhibitor of cytidine deaminase (CDA).8,12-14  The transition-state 
hypothesis that led us to postulate zebularine as a mechanism-based inhibitor of CDA 
was examined in detail15 and later confirmed by X-ray crystallography showing the 
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hydrated 2-(1H)-pyrimidinone ring of zebularine (7) complexed with zinc at the active 
site of the enzyme.16,17  
Scheme 1 
Structures 6-8 
As a CDA inhibitor zebularine was about 10-fold less potent than the prototypic 
inhibitor tetrahydrouridine (THU, 8) with a Ki of 2 μM.8 However, in contrast to THU it 
showed good stability, particularly to acid (vide infra), making it a useful adjuvant for 
oral administration with drugs readily deaminated by CDA, such as arabinofuranosyl 
cytosine (ara-C),9,18 and 2’-deoxy-5-azacytidine.19  Our observation that zebularine was 
additionally cytotoxic to culture L1210 and P388 leukemia cells prompted the 
examination of its antitumor properties in vivo.  Employing a standard NCI testing 
protocol,20 intraperitoneal tumor implantation and intraperitoneal drug treatment (ip/ip) 
produced increases in life span (ILS) as high as 93% at 800 mg/Kg (Table 1).9 Following 
oral treatment, good activity (81%-112% ILS) was also obtained with either ip or 
subcutaneous (sc) L1210 tumor implantation.9  The relative high doses employed were 
indicative of the low toxicity of zebularine, which was ascertained by the difference in 
weight between drug-treated and untreated control mice.  In contrast to zebularine, the 2’-
deoxy and ara derivatives showed essentially no cytotoxicity against L1210 cells at 
concentrations of  > 100 μM.21 Of the few 5-substituted zebularine analogues 
synthesized, the 5-fluoro analogue (5b) was the most potent inhibitor of CDA with a Ki 
value equivalent to that of THU.8  This in vitro potency carried over to in vivo antitumor 
activity which was about the same as zebularine’s (50-50% ILS) against murine P388 
leukemia but 100 times more potent under the same experimental conditions.9  Against 
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L1210 leukemia, it was also significantly more active than zebularine (140% ILS versus 
90%) with the same 100-fold increase in potency.9  The down side was that 5-
fluorozebularine appeared to be more toxic and less stable than zebularine.  
Table 1 
STRUCTURE-ACIVITY RELATIONSHIP: FROM A CDA INHIBITOR TO A 
CYTOSINE-C5-METHYLTRANSFERASE INHIBITOR 
 
As described 1991,9 we understood that zebularine had antitumor activity, but 
could not identify or propose a suitable molecular target.  It was through our long-
standing collaboration with Sheldon Greer of the University of Miami, who had been 
studying the effect of the radiosensitizer agent, 5-chloro-2’-deoxycytidine (CldC, 
cytochlor)22 in combination with CDA inhibitors, that zebularine was tested as a DNA 
methylase inhibitor.   Since it was possible that cytochlor when incorporated into DNA 
could induce hypomethylation of tumor DNA in the same manner as reported for 5-
fluoro-2’-deoxycytidine,23 he proposed to test separately both agents of the combination, 
CldC and zebularine, as DNA methylase inhibitors.   The initial discovery in the 
laboratory of Eric Selker at the University of Oregon showing that zebularine reactivated 
a silenced hph gene in Neurospora by inhibiting DNA methylation was immediately 
corroborated in Peter Jone’s laboratory at USC, who recently confirmed that indeed 
zebularine was capable of reactivating a silenced tumor suppressor gene (p16) both in 
vitro and in vivo.24  In chemical terms, provided that zebularine gets incorporated into 
DNA, the results can be explained by the increased electrophilic character of the 2-(1H)-
pyrimidinone ring of zebularine relative to cytosine brought about by the absence of the 
electron donating amino group.   We had already shown that water could nucleophilically 
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add across the 3,4-double bond of zebularine to give a covalent hydrated C4-adduct (7) at 
the active site of CDA.16,17  Independently, we also observed the formation of a stable 
intramolecular C6-adduct (9), which provided direct chemical evidence that the 2-(1H)-
pyrimidinone ring of zebularine was also susceptible to nucleophilic attacked at the C6 
positions by a hydroxyl group (Scheme 2).25,26   Attack by water at C4 would then lead to 
CDA inhibition (5c, Nuc = OH), whereas attack at C6 by other nucleophiles could 
explain the antibacterial activity of zebularine against E. coli via inhibition of 
thymidylate synthase,27 and the now observed inhibition of cytosine-C5-
methyltransferase, since both catalytically similar reactions are initiated by nucleophilic 
attack at C6 by a thiol group of an invariant cysteine residue (5d, Nuc = SH).28 In vitro 
experiments with synthetic oligodeoxynucleotides (ODNs) containing the 2-(1H)-
pyrimidinone ring of zebularine at the target site for methylation have been shown to 
form tight complexes with bacterial methyltransferases.29-31 These results support a 
mechanism-based inhibition of the enzyme resulting from the formation of a covalent 
bond between a conserved cysteine residue and the C6 carbon of the pyrimidine ring.  In 
agreement with our simple chemical observation that ‘harder” oxygen nucleophiles can 
also react with the ring to form a compound such as 9, serine and threonine amino acids 
can replace the active cysteine residue of the M.MspI DNA methylase and still form a 
covalent complexe with the enzyme.31  Mechanistically, these reactions are facilitated by 
an enzyme-mediated base-flipping of the 2-(1H)-pyrimidinone ring at the target site for 
methylation in the same manner as described for 5-fluorocytosine.32 This base-flipping 
mechanism is further enhanced by the weaker hydrogen bonding of the 2-(1H)-
pyrimidinone:guanine base pair relative to the native C:G base pair.33   Recently, a 13-
 5
mer ODN containing a 5’-GXGC-3’/5’-GCGC-3’ with the 2-(1H)-pyrimidinone ring of 
zebularine (X) at the target site was shown by X-ray crystallography to appear with the 
base rotated out of the helix and into the catalytic pocket forming the expected covalent 
complex of as in 5d (Nuc = SH) with the enzyme M.HhaI.34  
Scheme 2 
DIRECT COMPARISON OF ODNs CONTAINING 5-AZACYTOSINE AND 2-
(1H)-PYRIMIDINONE AT THE SAME TARGET POSITION FOR 
METHYLATION 
 
Although 5-azacytidine (10a) and 2’-deoxy-5-azacytidine (10b) are structurally 
different from zebularine (5a), they share similar chemical properties affiliated with the 
increase reactivity at the C6 position of the heterocyclic ring relative to cytosine.  
However, the question of how these compounds compare with zebularine in terms of 
their enhanced electrophilic character remained unanswered.   In the case of 10a and 10b, 
the C5 → N5 substitution is responsible for the enhanced electrophilicity, whereas in the 
case of zebularine it is the removal of the exocyclic 4-amino group from cytosine that 
brings about a similar change.  Since an identical serine mutant described above for 
zebularine was also capable of interacting covalently with 5-azacytosine,35 one would 
expect comparable potencies for both compounds.  However, the only way to 
unequivocally answer this question was to compare identical ODN sequences differing 
only in the nature of the base at the target site and measuring the inhibition of methyl 
transfer to a standard ODN substrate.  Since a small hemimethylated 13-mer ODN with 
5-fluorocytosine substituted for the target cytosine (underlined) in the M.HhaI 
recognition sequence 5’-GCGC-3’ had been shown to act as a strong DNA methylase 
inhibitor,32 identical 13-mer sequences were selected for comparing 5-azacytosine and 2-
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(1H)-pyrimidinone.   The synthesis of an ODN containing 5-azacytosine at the same 
target site has already been reported.36   The equivalent synthesis of the 2-(1H)-
pyrimidinone-ODN was performed in a 1 μmol scale using commercially available 2-
cyanoethyl phosphoramidites of the natural bases and the 5’-O-DMT-2’-
deoxyzebularine-3’-O-2-cyanoethyl-N,N-diisopropylphosphoramidite which was 
synthesized and fully characterized.  The final condition for deprotection and cleavage of 
the 13-mer from the solid support, which minimized the decomposition of zebularine, 
was a brief, 30 min treatment with concentrated ammonium hydroxide at 50 °C, which is 
much simpler than previous methods reported in the literature.33,37  Mass spectrometry 
analysis confirmed the mass expected for the desired 13-mer.   
Structures 10a and 10b 
Herein we compare vis-à-vis the relative inhibitory potency of a double-stranded 
ODN containing 5-azacytosine (X)36 and the corresponding double-stranded ODN 
containing 2-(1H)-pyrimidinone (Y) in the presence of a 24 bp long ODN substrate with 
a single hemimethylated 5’-GCGC-3’ target site [5-methylcytosine (M) opposite to the 
target C].  The substrate OND was mixed with increasing concentrations of the inhibitor 
ODNs (15-120 nM) and the methylation reactions were initiated by adding the substrate-
inhibitor mix to a standard reaction mixture containing 8.6 nM M.HhaI and 2.43 μM 
AdoMet as the methyl donor.  The rate of incorporation of radiolabeled methyl groups 
from [methyl-3H]AdoMet (Figure 1) indicated that the inhibitory potency of the 2-(1H)-
pyrimidinone-containing ODN was virtually identical to that of the ODN substituted with 
5-azacytosine.36   
Figure 1 
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Gel shift assays were also used to evaluate the influence of cofactors and thermal 
stability on the covalent interaction between M.HhaI and the 2-(1H)-pyrimidinone-ODN 
under denaturating conditions.  The same double-stranded 2-(1H)-pyrimidinone-ODN 
with 32P-radiolabel at the 5’-end was incubated with M.HhaI for 30 min at various 
temperatures in the presence of AdoMet, AdoHcy or in the absence of cofactor.  
Complexes maintained at 4 °C and 22 °C were found to have the same electrophoretic 
mobility in both native (data not shown) and denaturating gels regardless of whether 
cofactor was present or not (Figure 2, lanes 1-6).  When heated to 50 °C, the presence of 
the high mobility complex without cofactors was significantly reduced, while cofactors 
were able to stabilize the complex against dissociation by heat in the presence of 1% SDS 
and β-mercaptoethanol (lanes 7-9).  The enhanced capacity of AdoMet over AdoHcy to 
stabilize the complex at higher temperature was evidenced when the same experiment 
was conducted at 75 °C (lanes 10-12).    The experiments shown in Figures 1 and 2 
confirmed that the inhibitor capacity of an ODN with the 2-(1H)-pyrimidinone 
substitution is virtually identical to the equivalently substituted ODN with 5-
azacytosine.36  
Figure 2 
POTENCY: THE ROLE OF METABOLISM AND CHEMICAL STABILITY 
 The chemical instability of 5-azacytosine-containing nucleosides (10a and 10b), 
even under neutral conditions, is well documented.38  On the other hand, zebularine 
appears to be quite stable with a half-lives of 44 and 68 hours at pH 1.0 and 2.0, 
respectively.  Furthermore, zebularine is completely stable at pH 5, and at pH 7.4 the 
half-life is 508 hours.   This enhanced chemical stability is perhaps responsible for the 
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oral activity of zebularine in the reactivation of silenced p16 expression24 and general 
antitumor activity.9   At higher, non-physiological pH values the drug does decompose 
and its decomposition products have been thoroughly characterized.39    Despite the fact 
that both classes of drugs have equal inhibitory potency as DNA methylase inhibitors 
when compared as  components of small ODN fragments, 5-azacytidine (10a) and 2’-
deoxy-5-azacytidine (10b) are ca. 30-fold and 300-fold more potent, respectively, than 
zebularine in inducing demethylation when used as single drugs.24   This disparity can be 
attributed to a more inefficient metabolism of zebularine compared to both 5-azacytidine 
and 2’-deoxy-5-azacytidine.  The metabolism of the latter two drugs is fairly well 
understood (Figure 3),40 while that of zebularine is still under investigation.  Tentatively, 
as indicated in Figure 4, we presume that zebularine will behave as a substrate for 
uridine/cytidine kinase.   Because only 2’-deoxyzebularine is expected to be incorporated 
into DNA, the conversion of zebularine-5’-diphosphate to 2’-deoxyzebularine-5’-
diphosphate by ribonucleotide reductase represents an additional rate-limiting step.   This 
metabolically costly cross-over is probably the reason why 2’-deoxy-5-azacytidine is 
active at one-tenth the concentration of 5-azacytidine.24  For that reason, we tested 2’-
deoxyzebularine with the intent to overcome the reduced potency of zebularine.  
Unfortunately, 2’-deoxyzebularine did not inhibit DNA methylation.24  Perhaps 
deoxycytidine kinase, the most likely enzyme to phosphorylate 2’-deoxyzebularine, does 
not recognize or bind well to this compound because it lacks the 4-amino group on the 
pyrimidine ring.  The metabolic activation of zebularine to 2’-deoxyzebularine-5’-
triphosphate and the determination of levels of incorporation into DNA and RNA are 
currently under investigation.   
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Figure 3 
Figure 4 
CONCLUSION 
  The identical level of inhibition of methyl transfer achieved with short ODNs 
containing either 5-azacytosine or 2-(1H)-pyrimidinone at the target site for methylation 
leads us to propose that once incorporation into DNA has been achieved, zebularine and 
5-azacytidine (or 2’-deoxy-5-azacytidine) are similarly potent against DNA (cytosine-C5) 
methyltransferase.   Despite the favorable chemical stability of zebularine that facilitates 
even oral administration of the drug, there appears to be a metabolic rate-limiting step for 
zebularine, either at the level of phosphorylation by uridine/cytidine kinase or at the level 
of ribonucleotide reductase, that reduces considerably the potency of the drug.   However, 
despite this shortcoming zebularine presents itself as a drug that may be clinically useful 
to reverse DNA methylation with minimal toxicity.   Perhaps the toxicity of zebularine 
reflects incorporation into RNA.  
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Table 1. Antitumor Activity of zebularinea 
 
Tumor 
(implantation)b 
Dose (route of 
administration) 
mg/Kg 
Weight change 
difference (g) 
% ILS 
P388 (ip) 400 (ip) -2.3 52 
L1210 (ip) 400 (ip) -2.1 75 
L1210 (ip) 800 (ip) -2.5 93 
L1210 (ip) 800 (po) -0.6 77 
L1210 (ip) 1600 (po) -2.3 112 
L1210 (sc) 800 (po) -0.8 81 
aAdapted from reference 9. bip = intraperitoneal; po = oral treatment; sc = subcutaneous. 
 
 
Figure legends: 
 
 
Figure 1. Relative Inhibition of M.HhaI 
 
Figure 2. Binding of Zebularine 13-mer to M.HhaI 
 
Figure 3. Metabolism of 5-Aza Nucleosides 
 
Figure 4. Metabolism of Zebularine 
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Structures 6-8 
 
 
 
Structures 10a,b 
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